Opinion|Videos|April 14, 2025
Evidence Supporting 2024 Guidance for Lp(a) Testing
Experts discuss the evidence supporting the National Lipid Association’s (NLA) recommendation for universal lipoprotein(a) (Lp[a]) measurement and evaluate how compelling this evidence is from a clinical perspective.
Advertisement
Video content above is prompted by the following:
- What evidence supported the NLA’s recommendation?
- How compelling is this evidence from a clinical perspective?
Advertisement
Related to this article
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
3
Drug Price Drives Value of MASH Therapies More Than Efficacy
4
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
5